Skip to main content
JADPRO Live 2024 Main banner
Icon Legend
ICONS KEY
CE Credit Available
CE Credit Available
Pharmacology Credit Available
Pharmacology Credit Available
Poster Activities
Poster Activities
Surgical Oncology
Surgical Oncology

Full Schedule

  1. Home
  2. Full Schedule

Full Schedule

  • Friday, November 15, 2024
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer
    GSK
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: CARVYKTI® Product Summary for Patient Care Teams
    Johnson & Johnson
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: Supporting Patients With HR+/HER2- mBC Throughout Their Treatment Journey
    Pfizer, Inc.
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: Treatment Option for Patients with Unresectable or Metastatic Melanoma​
    Bristol Myers Squibb
  • 7:00 AM – 8:15 AM CT
    Exhibit Hall Open & Continental Breakfast
  • 7:00 AM – 5:30 PM CT
    Registration
  • 8:20 AM – 8:30 AM CT
    Welcome & Opening Remarks
  • 8:30 AM – 9:45 AM CT
    Opening Panel Discussion: Understanding the Benefits and Pitfalls of Artificial Intelligence in Oncology
  • 9:45 AM – 4:30 PM CT
    Braindate
  • 9:50 AM – 10:50 AM CT
    Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide
  • 9:50 AM – 10:50 AM CT
    New Drug Updates in Solid Tumors
  • 10:50 AM – 11:20 AM CT
    APSHO Meet & Greet: Awards & Recognition Committee
  • 10:50 AM – 11:50 AM CT
    Exhibit Hall Open & Refreshment Break
  • 11:05 AM – 11:35 AM CT
    Exhibit Hall Presentation Theater: Clinical Considerations for the Treatment of mTNBC and HR+/HER2- mBC with an ADC
    Gilead
  • 11:05 AM – 11:35 AM CT
    Exhibit Hall Presentation Theater: Explore the current data that could help you recognize/assess candidates for a CDK4 & 6 inhibitor.
    Lilly
  • 11:05 AM – 11:50 AM CT
    Exhibit Hall Presentation Theater: Practical Management of AML with a BCL-2 Inhibitor
    AbbVie
  • 11:20 AM – 11:50 AM CT
    APSHO Meet & Greet: Communications Committee
  • 11:50 AM – 12:35 PM CT
    Cancer Complexities: Balancing Your Patient’s Comorbidities With Their Treatments
  • 11:50 AM – 12:35 PM CT
    Updates in HR-Positive HER2-Negative Metastatic Breast Cancer for the Advanced Practitioner
  • 12:25 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: The AEGEAN Regimen: Neoadjuvant IMFINZI® (durvalumab) + Platinum-Containing Chemotherapy Then Adjuvant IMFINZI for Resectable (Tumors ≥4 cm and/or Node Positive) NSCLC With No Known EGFR Mutations or ALK Rearrangements
    AstraZeneca
  • 12:25 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: Thrombotic Risk and Symptom Assessment in Patients With Polycythemia Vera | A Collaborative Approach to Identifying When to Intervene With Jakafi® (ruxolitinib)
    Incyte Corporation
  • 12:35 PM – 2:00 PM CT
    Exhibit Hall Open & Lunch
  • 12:35 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: A Consideration for Patients With Relapsed or Refractory Multiple Myeloma
    Johnson & Johnson
  • 12:35 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: Review of evidence-based data for an antibody-drug conjugate in combination with a PD-1 inhibitor for 1L la/mUC
    Astellas Pharma Inc. and Pfizer Oncology Inc.
  • 12:35 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: Subcutaneous Administration: An Alternative Route of Administration in Oncology Treatment​
    Bristol Myers Squibb
  • 1:15 PM – 1:45 PM CT
    APSHO Meet & Greet: Diversity Equity & Inclusion (DEI) Committee
  • 2:00 PM – 3:00 PM CT
    Keynote Address: The Resilience Blueprint: Navigating Change in the New Normal
  • 3:00 PM – 3:30 PM CT
    APSHO Meet & Greet: Board of Directors
  • 3:00 PM – 3:45 PM CT
    Moderated Posters: Clinical Posters, Industry Encore Posters, and APSHO Patient Advocacy Posters
  • 3:00 PM – 4:00 PM CT
    Exhibit Hall Open & Refreshment Break
  • 3:15 PM – 3:45 PM CT
    Exhibit Hall Presentation Theater: Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Amgen
  • 3:15 PM – 3:45 PM CT
    Exhibit Hall Presentation Theater: Utilizing Gene Expression Profile (GEP) testing to Personalize Management for Patients with Cutaneous Malignancies
    Castle Biosciences
  • 3:15 PM – 3:45 PM CT
    ymphocytic Leukemia and Waldenström Macroglobulinemia Patient Populations
    Supported by Pharmacyclics, An Abbvie Company and Johnson & Johnson
  • 3:30 PM – 4:00 PM CT
    APSHO Meet & Greet: Membership Committee
  • 3:45 PM – 4:15 PM CT
    Updates in the Surgical Management of Small Renal Tumors
  • 3:45 PM – 4:45 PM CT
    Successful Management of Patients Receiving Bispecific Antibodies for Hematologic Malignancies
  • 3:45 PM – 5:00 PM CT
    Oral Poster Presentations (Part 1)
  • 4:15 PM – 4:45 PM CT
    Updates in the Surgical Management of Small Lung Tumors
  • 5:00 PM – 5:45 PM CT
    Independent CE-Accredited Satellite Symposium: Treatment Advances For Advanced Prostate Cancer: Guideline Updates and Newer Therapies
  • 5:45 PM – 6:30 PM CT
    Independent CE-Accredited Satellite Symposium: Opportunities for Improved Outcomes: The Role of Targeted Therapies in Metastatic Urothelial Carcinoma
  • 6:30 PM – 8:30 PM CT
    Independent CE-Accredited Dinner Satellite Symposium: Optimizing the Patient Journey in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Evolving Guidelines, Emerging Options, and Multidisciplinary Management Strategies